Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

BACKGROUND: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Koutaroh, Araki, Mitsugu, Sakashita, Takuya, Ma, Biao, Kanada, Ryo, Yanagitani, Noriko, Horiike, Atsushi, Koike, Sumie, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Maemondo, Makoto, Nishio, Makoto, Ishikawa, Takeshi, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441848/
https://www.ncbi.nlm.nih.gov/pubmed/30662002
http://dx.doi.org/10.1016/j.ebiom.2019.01.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441848/
https://www.ncbi.nlm.nih.gov/pubmed/30662002
http://dx.doi.org/10.1016/j.ebiom.2019.01.019

Ejemplares similares